Literature DB >> 8144948

Induction of allograft tolerance in rats by an HLA class-I-derived peptide and cyclosporine A.

S Nisco1, P Vriens, G Hoyt, S C Lyu, F Farfan, P Pouletty, A M Krensky, C Clayberger.   

Abstract

T cell recognition of MHC molecules initiates a cascade of events resulting in allograft rejection. CTLs damage the graft by targeting nonself-MHC class I molecules. We and others have previously shown that small synthetic peptides corresponding to regions of certain MHC class I molecules can inhibit the CTL response against MHC class I alloantigens in vitro. Here we report that rat heart allografts survived survived indefinitely when transplanted into recipients treated with a synthetic peptide corresponding to residues 75-84 of (B7.75-84) in combination with a subtherapeutic dose of cyclosporine A. Furthermore, this treatment induced long-term donor-specific tolerance that was mediated by anergic cells, indicating that such peptides may have potential as therapeutics for human organ transplantation.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8144948

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  11 in total

1.  A human class II MHC-derived peptide antagonizes phosphatidylinositol 3-kinase to block IL-2 signaling.

Authors:  M L Boytim; P Lilly; K Drouvalakis; S C Lyu; R Jung; A M Krensky; C Clayberger
Journal:  J Clin Invest       Date:  2000-05       Impact factor: 14.808

Review 2.  Prospects for induction of tolerance in renal transplantation.

Authors:  A M Krensky; C Clayberger
Journal:  Pediatr Nephrol       Date:  1994-12       Impact factor: 3.714

Review 3.  Immunologic tolerance in renal transplantation.

Authors:  D A Shoskes
Journal:  World J Urol       Date:  1996       Impact factor: 4.226

4.  Peptides of a major histocompatibility complex class I (Kb) molecule cause prolongation of skin graft survival and induce specific down-regulatory T cells demonstrable in the mixed lymphocyte reaction.

Authors:  B D Brondz; D B Kazansky; A D Chernyshova; V S Ivanov
Journal:  Immunology       Date:  1995-10       Impact factor: 7.397

5.  Antibodies to a conserved region of HLA class I molecules, capable of modulating CD8 T cell-mediated function, are present in pooled normal immunoglobulin for therapeutic use.

Authors:  S Kaveri; T Vassilev; V Hurez; R Lengagne; C Lefranc; S Cot; P Pouletty; D Glotz; M D Kazatchkine
Journal:  J Clin Invest       Date:  1996-02-01       Impact factor: 14.808

6.  RDP1258, a new rationally designed immunosuppressive peptide, prolongs allograft survival in rats: analysis of its mechanism of action.

Authors:  M C Cuturi; F Christoph; J Woo; S Iyer; S Brouard; J M Heslan; P Pignon; J P Soulillou; R Buelow
Journal:  Mol Med       Date:  1999-12       Impact factor: 6.354

7.  Peptide vaccination can lead to enhanced tumor growth through specific T-cell tolerance induction.

Authors:  R E Toes; R Offringa; R J Blom; C J Melief; W M Kast
Journal:  Proc Natl Acad Sci U S A       Date:  1996-07-23       Impact factor: 11.205

Review 8.  Prevention of transplant rejection: current treatment guidelines and future developments.

Authors:  N Perico; G Remuzzi
Journal:  Drugs       Date:  1997-10       Impact factor: 9.546

9.  Class I MHC allochimeric presentation of composite immunogenic and self epitopes induces tolerance to genetically diverse rat strains.

Authors:  Natalya V Semiletova; Xiu-Da Shen; Daniel M Feldman; Feng Gao; Ana Mhoyan; Dhai Liu; Ronald W Busuttil; Jerzy W Kupiec-Weglinski; Rafik M Ghobrial
Journal:  Cell Immunol       Date:  2007-10-23       Impact factor: 4.868

10.  Vascularized composite allograft rejection is delayed by intrajejunal treatment with donor splenocytes without concomitant immunosuppressants.

Authors:  Christopher Glenn Wallace; Chia-Hung Yen; Hsiang-Chen Yang; Chun-Yen Lin; Ren-Chin Wu; Wei-Chao Huang; Jeng-Yee Lin; Fu-Chan Wei
Journal:  Clin Dev Immunol       Date:  2012-11-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.